FDA expands approval for Otsuka's antipsychotic drug: 3 things to know

The Food and Drug Administration on Friday approved a new use for Otsuka Pharmaceutical Co.'s drug Abilify Maintena.

Here are three things to know.

  1. Abilify Maintena is a once-daily injectable antipsychotic drug for intramuscular use.

  1. The agency first approved the drug in 2013 to treat schizophrenia.

  1. Abilify Maintena may now be used as a monotherapy for adults with bipolar I disorder.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars